Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vijay Patil

Showing results (81-90 of 189) with videos related to

Pageof 19
Sort By:
Ecancermedicalscience|September 8, 2022
ALK-positive advanced non-small cell lung cancer patients with poor performance status: Outcomes in a real-world scenarioAjaykumar Singh, Akhil Kapoor, Vanita Noronha, et al.
South Asian Journal of Cancer|January 21, 2020
Third-line therapy in the epidermal growth factor receptor mutation-positive advanced nonsmall-cell lung cancerVanita Noronha, Nikhil Pande, Amit Joshi, et al.
Oral Oncology|September 20, 2022
Long term outcomes of a randomized controlled clinical trial comparing the efficacy of Cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancerVijay Patil, Sravan Kumar, Vanita Noronha, et al.
The Bone & Joint Journal|September 30, 2020
Infographic: The effects of COVID-19 on perioperative morbidity and mortality in patients with hip fracturesBabar Kayani, Elliot Onochie, Vijay Patil, et al.
World Neurosurgery|July 10, 2021
Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant ChemotherapySachith Anand, Abhishek Chatterjee, Tejpal Gupta, et al.
World Neurosurgery|February 22, 2022
Optimizing Postoperative Adjuvant Therapy in Elderly Patients with Newly Diagnosed Glioblastoma: Single-Institution Audit of Clinical Outcomes from a Tertiary-Care Comprehensive Cancer Center in IndiaAbhishek Chatterjee, Manish Bhadane, Jifmi Jose Manjali, et al.
BMJ Open|March 17, 2021
Standard maintenance therapy versus local consolidative radiation therapy and standard maintenance therapy in 1-5 sites of oligometastatic non-small cell lung cancer: a study protocol of phase III randomised controlled trialAnil Tibdewal, Jai Prakash Agarwal, Shashank Srinivasan, et al.
Nuclear Medicine Communications|January 16, 2020
Differentiating dural metastases from meningioma: role of 68Ga DOTA-NOC PET/CTNilendu C Purandare, Ameya Puranik, Sneha Shah, et al.
Ecancermedicalscience|February 25, 2022
Efficacy and safety of neoadjuvant chemotherapy (NACT) with paclitaxel plus carboplatin and oral metronomic chemotherapy (OMCT) in patients with technically unresectable oral squamous cell carcinoma (OSCC)Lakhan Kashyap, Vijay Patil, Vanita Noronha, et al.
European Journal of Clinical Pharmacology|June 13, 2020
Safety and CSF distribution of high-dose erlotinib and gefitinib in patients of non-small cell lung cancer (NSCLC) with brain metastasesBharati Shriyan, Deepali Patil, Murari Gurjar, et al.
Pageof 19

Showing results (81-90 of 189) with videos related to

Sort By:
Pageof 19
Ecancermedicalscience|September 8, 2022
ALK-positive advanced non-small cell lung cancer patients with poor performance status: Outcomes in a real-world scenarioAjaykumar Singh, Akhil Kapoor, Vanita Noronha, et al.
South Asian Journal of Cancer|January 21, 2020
Third-line therapy in the epidermal growth factor receptor mutation-positive advanced nonsmall-cell lung cancerVanita Noronha, Nikhil Pande, Amit Joshi, et al.
Oral Oncology|September 20, 2022
Long term outcomes of a randomized controlled clinical trial comparing the efficacy of Cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancerVijay Patil, Sravan Kumar, Vanita Noronha, et al.
The Bone & Joint Journal|September 30, 2020
Infographic: The effects of COVID-19 on perioperative morbidity and mortality in patients with hip fracturesBabar Kayani, Elliot Onochie, Vijay Patil, et al.
World Neurosurgery|July 10, 2021
Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant ChemotherapySachith Anand, Abhishek Chatterjee, Tejpal Gupta, et al.
World Neurosurgery|February 22, 2022
Optimizing Postoperative Adjuvant Therapy in Elderly Patients with Newly Diagnosed Glioblastoma: Single-Institution Audit of Clinical Outcomes from a Tertiary-Care Comprehensive Cancer Center in IndiaAbhishek Chatterjee, Manish Bhadane, Jifmi Jose Manjali, et al.
BMJ Open|March 17, 2021
Standard maintenance therapy versus local consolidative radiation therapy and standard maintenance therapy in 1-5 sites of oligometastatic non-small cell lung cancer: a study protocol of phase III randomised controlled trialAnil Tibdewal, Jai Prakash Agarwal, Shashank Srinivasan, et al.
Nuclear Medicine Communications|January 16, 2020
Differentiating dural metastases from meningioma: role of 68Ga DOTA-NOC PET/CTNilendu C Purandare, Ameya Puranik, Sneha Shah, et al.
Ecancermedicalscience|February 25, 2022
Efficacy and safety of neoadjuvant chemotherapy (NACT) with paclitaxel plus carboplatin and oral metronomic chemotherapy (OMCT) in patients with technically unresectable oral squamous cell carcinoma (OSCC)Lakhan Kashyap, Vijay Patil, Vanita Noronha, et al.
European Journal of Clinical Pharmacology|June 13, 2020
Safety and CSF distribution of high-dose erlotinib and gefitinib in patients of non-small cell lung cancer (NSCLC) with brain metastasesBharati Shriyan, Deepali Patil, Murari Gurjar, et al.
Pageof 19